Omalizumab
- PDF / 169,511 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 29 Downloads / 181 Views
1
Omalizumab Fatigue: 2 case reports In a retrospective study involving 13 patients, two patients [sexes and ages not stated] were described, who developed fatigue immediately after receiving omalizumab [routes not stated] for hereditary α-tryptasemia (HαT). One patient was scheduled to receive omalizumab injection 300mg every 2 weeks and other patient was scheduled to receive 150mg every 4 weeks. Both the patients had not reported baseline fatigue prior to receiving omalizumab [durations of treatments to reactions onsets and outcome not stated]. Author comment: "[T]his report provides initial evidence of a role for omalizumab in management of selected individuals with HαT". "Two individuals who did not report baseline fatigue developed fatigue while taking omalizumab." Mendoza Alvarez LB, et al. Clinical response to omalizumab in patients with hereditary alpha-tryptasemia. Annals of Allergy, Asthma and Immunology 124: 99-100, No. 1, Jan 2020. Available from: URL: http://doi.org/10.1016/ 803443596 j.anai.2019.09.026 - USA
0114-9954/20/1785-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 4 Jan 2020 No. 1785
Data Loading...
